Insilico Medicine (03696) saw its shares jump nearly 15% in early trading. At the time of writing, the stock was up 10.14%, trading at HK$63 with a turnover of HK$216 million.
The company announced a drug discovery collaboration with Eli Lilly. This partnership will leverage Insilico Medicine's AI engine to accelerate the discovery and development of novel therapies across multiple therapeutic areas. Under the agreement terms, Insilico Medicine is eligible to receive an upfront payment of $115 million, with additional payments upon achieving development, regulatory, and commercial milestones, potentially bringing the total deal value to approximately $2.75 billion. Furthermore, Insilico Medicine will also receive tiered royalties based on future sales.
Additionally, Insilico Medicine's 2025 performance report indicated that, driven by its dual-engine strategy of "AI + Biopharma," the company has steadily advanced its business development during the reporting period and up to the latest practicable date. It has established drug research and development partnerships, out-licensing agreements, and other collaborations with more than 10 multinational pharmaceutical companies or leading domestic biopharmaceutical firms. The total value of new contracts signed reached $1.3 billion, with the cumulative value of major partnerships since 2021 amounting to $4.6 billion.
Comments